首页 | 本学科首页   官方微博 | 高级检索  
检索        

液质联用测定血浆中阿奇霉素及其人体药动学和相对生物利用度研究
引用本文:王玉花,陈俊杰,陈本美,张毕奎.液质联用测定血浆中阿奇霉素及其人体药动学和相对生物利用度研究[J].中国药学杂志,2006,41(1):51-53.
作者姓名:王玉花  陈俊杰  陈本美  张毕奎
作者单位:1. 中南大学湘雅二医院临床药学研究室,长沙,410009
2. 中南大学现代分析测试中心生物分析化学研究室,长沙,410009
摘    要: 目的建立人血浆中阿奇霉素的高效液相色谱-质谱测定方法,用于研究阿奇霉素分散片的人体药动学及相对生物利用度。方法血浆样品中加入内标克拉霉素后,经乙酸乙酯提取,采用高效液相色谱-质谱法,电喷雾电离源选择性正离子峰检测。用建立的方法测定18名健康男性志愿者单剂量口服阿奇霉素分散片实验制剂或参比制剂的体内经时过程,由血药浓度数据获得各自的药动学参数,以双单侧t检验进行生物等效性判定。结果在2.5~800μg·L-1内呈良好的线性关系,r= 0.999 3,平均回收率为98.1%,日内RSD≤11.3%,日间RSD≤8.6%,单次服用500 mg阿奇霉素分散片实验制剂或参比制剂后的药动学参数AUC0-120,ρmax,tmax,t1/2分别为(5 856.5±1 423.6)和(6 096.8±1 111.0)μg·h·L-1,(520.1±94.1)和(558.8± 74.0)μg·L-1,(1.4±0.4)和(1.3±0.2)h,(36.1±10.2)和(36.2±11.7)h。相对生物利用度为(96.3±16.0)%。结论该方法灵敏度高,无杂质干扰,结果准确。测得的实验制剂与参比制剂的主要药动学参数之间无明显差异,两种片剂为生物等效制剂。

关 键 词:阿奇霉素  高效液相色谱-质谱  药动学  生物利用度
文章编号:1001-2494(2006)01-0051-04
收稿时间:2005-04-07
修稿时间:2005-04-07

Determination of Azithromycin in Human Plasma by HPLC-MS and Its Relative Bioavailability
WANG Yu-hua,CHEN Jun-jie,CHEN Ben-mei,ZHANG Bi-kui.Determination of Azithromycin in Human Plasma by HPLC-MS and Its Relative Bioavailability[J].Chinese Pharmaceutical Journal,2006,41(1):51-53.
Authors:WANG Yu-hua  CHEN Jun-jie  CHEN Ben-mei  ZHANG Bi-kui
Institution:1.Clinic Pharmacy Research Laboratory,Second Xiangya Hospital of Central South University,Changsha 410011,China[2.Bioanalytical Chemistry Research Laboratory, Modern Analytical Testing Center,Central South University,Changsha 410011,China
Abstract:OBJECTIVE To determine azithromycin in human plasma by a HPLC-MS method, and to study its relative bioavailabili-ty.METHODS Azithromycin concentrations in plasma were determined by HPLC-MS.The test and reference formulations of azithromycin were given to 18 healthy male volunteers. Bioequivalence was determined by a two one-side t-tests.RESULTS The calibration curve was linear within the range of 2.5~800 μg·L-1(r= 0.999 3) ,the recovery was 98.1% , the RSDs of intra-and inter-day were no more than 11.3% and 8.6% .After a single oral dose of 500 mg azithromycin test or reference dispersible tablet,the main pharmacokinetic parameters were as follows: AUC0~120(5 856.5±1 423.6) and (6096.8±1 111.0)μg·h·L-1,ρmax(520.1±94.1) and (558.8±74.0)μg·L-1,tmax(1.4±0.4) and (1.3±0.2) h ,t1/2(36.1±10.2) and (36.2±11.7) h, respectively. Relative bioavailability was (96.3±16.0)%. CONCLUSION The method is accurate and sensitive with no endogenous interference. No significant difference exists among the main pharmacokinetic parameters for the test tablets and the reference tablets. The two formulations are bioequivalent.
Keywords:azithromycin  HPLC-MS  pharmacokinetics  bioavailability  
本文献已被 CNKI 万方数据 等数据库收录!
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号